

Eukarÿs wins the Galien MedStartUp 2019 Award



Evry, Tuesday, October 29, 2019,

Eukarÿs is proud to announce winning the Galien MedStartUp Award 2019 in the category of Best Collaboration with the Pharmaceutical or Biotechnology Industry. This highly prestigious award, presented Thursday, October 24 in New York at the Alexandria Life Sciences Center, recognizes the best scientific innovations for human health. Eukarÿs partnership with the University of Alberta's Molecular Virology and Oncology Laboratory, led by Dr. Maya Shmulevitz, has been recognized. This collaboration has led to the development of the C3P3 system for viral bioproduction applications, particularly reoviruses used oncolytically. This award was presented by a committee chaired by Bernard Poussot (President of Roche Holding) and comprising leaders of the largest companies in the pharmaceutical industry (Sanofi, GSK, Pfizer, Johnson & Johnson, UCB) and venture capital (EvercorePartners).

About Eukarÿs:

Eukarÿs is a French biotech company of the Evry Genopole Biocluster which is developing the first, and to date the only, eukaryotic artificial expression system called C3P3. This system allows the high-yield production of mature messenger RNAs and thus proteins of interest in the host cell. Through this system, Eukarÿs is developing a radically innovative approach to synthetic gene therapy that provides solutions to the challenges facing this new therapeutic area. Eukarÿs also uses the C3P3 system to develop high performance bioproduction systems for biologic drugs including proteins, recombinant viruses and VLP vaccines.